Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

The First Affiliated Hospital of Zhengzhou University300 enrolled

Overview

The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Esophageal Neoplasms

Interventions

an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitorDRUG

This is an observational study

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Esophageal cancer confirmed by histopathology or cytology 2. Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy 3. Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers 4. Patients who sign informed consent and voluntarily join the study Exclusion Criteria: 1. Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study 2. Patients who are undergoing treatment regimen of blind trial

Locations (1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

RECRUITING

Outcomes

Primary Outcomes

PFS

Progression Free Survival

Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Secondary Outcomes

Overall Survival

Time frame: From date of admission until the date of death from any cause, assessed up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.